A detailed history of Hantz Financial Services, Inc. transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 165 shares of LGND stock, worth $33,141. This represents 0.0% of its overall portfolio holdings.

Number of Shares
165
Previous 113 46.02%
Holding current value
$33,141
Previous $13,000 123.08%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 04, 2025

BUY
$112.56 - $177.14 $5,853 - $9,211
52 Added 46.02%
165 $29,000
Q2 2025

Aug 04, 2025

BUY
$96.67 - $118.22 $5,123 - $6,265
53 Added 88.33%
113 $13,000
Q1 2025

May 12, 2025

SELL
$105.14 - $122.23 $816,622 - $949,360
-7,767 Reduced 99.23%
60 $6,000
Q4 2024

Jan 23, 2025

BUY
$99.95 - $129.9 $782,308 - $1.02 Million
7,827 New
7,827 $839,000

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $3.39B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Hantz Financial Services, Inc. Portfolio

Follow Hantz Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hantz Financial Services, Inc. with notifications on news.